Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

NCT02128282 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

127

Enrollment

INDUSTRY

Sponsor class

Conditions

Cholangiocarcinoma

Interventions

DRUG: CX-4945
DRUG: Cisplatin
DRUG: Gemcitabine

Sponsor

Senhwa Biosciences, Inc.